LSD1 inhibitors can restore the expression of MHC-I (22) and potentiate responses to anti-PDL1 antibody for SCLC (23), which suggests that LSD1 inhibitors plus chemo-immunotherapy is a promising approach for ES-SCLC. Here, KDM1A is linked to small cell lung carcinoma.